MCID: TRC003
MIFTS: 44

Trichomoniasis

Categories: Infectious diseases, Nephrological diseases, Reproductive diseases

Aliases & Classifications for Trichomoniasis

MalaCards integrated aliases for Trichomoniasis:

Name: Trichomoniasis 12 77 56 44 3 15
Trichomonas Infections 45 74
Trichomonas Infection 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1947
ICD9CM 36 131 131.9
MeSH 45 D014245
NCIt 51 C35720
SNOMED-CT 69 56335008
ICD10 34 A59 A59.9
UMLS 74 C0040921

Summaries for Trichomoniasis

MedlinePlus : 44 Trichomoniasis is a sexually transmitted disease caused by a parasite. It spreads from person to person during sex. Many people do not have any symptoms. If you do get symptoms, they usually happen within 5 to 28 days after being infected. It can cause vaginitis in women. Symptoms include Yellow-green or gray discharge from the vagina Discomfort during sex Vaginal odor Painful urination Itching burning, and soreness of the vagina and vulva Most men do not have symptoms. If they do, they may have Itching or irritation inside the penis Burning after urination or ejaculation Discharge from the penis Trichomoniasis can increase the risk of getting or spreading other sexually transmitted diseases. Pregnant women with trichomoniasis are more likely to give birth too early, and their babies are more likely have a low birth weight. Lab tests can tell if you have the infection. Treatment is with antibiotics. If you are infected, you and your partner must be treated. Correct usage of latex condoms greatly reduces, but does not eliminate, the risk of catching or spreading trichomoniasis. The most reliable way to avoid infection is to not have anal, vaginal, or oral sex. Centers for Disease Control and Prevention

MalaCards based summary : Trichomoniasis, also known as trichomonas infections, is related to vaginitis and bacterial vaginosis, and has symptoms including fever, pruritus and pelvic pain. An important gene associated with Trichomoniasis is IL2 (Interleukin 2), and among its related pathways/superpathways are Immune response IFN alpha/beta signaling pathway and Photodynamic therapy-induced NF-kB survival signaling. The drugs Acetylcysteine and Metronidazole have been mentioned in the context of this disorder. Affiliated tissues include testes, spinal cord and cervix.

Disease Ontology : 12 A parasitic protozoa infectious disease that is caused by singled-celled protozoan parasites Trichomonas vaginalis or Trichomonas tenax, which infect the urogenital tract and mouth respectively.

CDC : 3 Trichomoniasis is common and easy to cure.

Wikipedia : 77 Trichomoniasis (trich) is an infectious disease caused by the parasite Trichomonas vaginalis. About 70%... more...

Related Diseases for Trichomoniasis

Diseases related to Trichomoniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Related Disease Score Top Affiliating Genes
1 vaginitis 33.1 CXCL8 LAP3
2 bacterial vaginosis 31.1 CXCL8 LAP3
3 urethritis 30.6 EXTL3 YME1L1
4 trichomonas vaginalis trichomoniasis 12.4
5 trichomonas tenax trichomoniasis 12.4
6 dientamoebiasis 11.6
7 candidiasis 10.6
8 chlamydia 10.4
9 infertility 10.4
10 vaginal discharge 10.3
11 campylobacteriosis 10.3
12 toxicodendron dermatitis 10.3 CXCL8 IL2
13 streptococcal toxic-shock syndrome 10.2 CXCL8 IL2
14 clonorchiasis 10.2 CXCL8 IL2
15 retinitis pigmentosa 44 10.2 CXCL8 IL2
16 crohn's colitis 10.2 CXCL8 IL2
17 capillary leak syndrome 10.2 CXCL8 IL2
18 asymptomatic neurosyphilis 10.2 CXCL8 EXTL3
19 necrotizing fasciitis 10.2 CXCL8 IL2
20 vulvovaginal candidiasis 10.2
21 wells syndrome 10.2 CXCL8 IL2
22 prostatitis 10.2 CXCL8 IL2
23 pleurisy 10.2 CXCL8 IL2
24 brucellosis 10.2 CXCL8 IL2
25 tonsillitis 10.2 CXCL8 IL2
26 cervical cancer 10.2
27 giardiasis 10.2
28 syphilis 10.2
29 human immunodeficiency virus infectious disease 10.2
30 herpes simplex 10.2
31 keratoconjunctivitis 10.1 CXCL8 IL2
32 conjunctivitis 10.1 CXCL8 IL2
33 visceral leishmaniasis 10.1 CXCL8 IL2
34 retinitis pigmentosa 10.1
35 diarrhea 10.1
36 vulvovaginitis 10.1
37 amebiasis 10.1
38 urethral syndrome 10.1 EXTL3 WASF3
39 primary bacterial infectious disease 10.1 CXCL8 EXTL3 IL2
40 bone inflammation disease 10.0 CXCL8 IL2
41 mastitis 10.0 CXCL8 SLPI
42 cervicitis 10.0 CXCL8 IL2 YME1L1
43 toxic shock syndrome 10.0 CXCL8 IL2
44 cystic fibrosis 9.9
45 human immunodeficiency virus type 1 9.9
46 pelvic inflammatory disease 9.9
47 trypanosomiasis 9.9
48 filariasis 9.9
49 anogenital venereal wart 9.9
50 urinary schistosomiasis 9.9

Comorbidity relations with Trichomoniasis via Phenotypic Disease Network (PDN):


Acute Cystitis Hypertension, Essential

Graphical network of the top 20 diseases related to Trichomoniasis:



Diseases related to Trichomoniasis

Symptoms & Phenotypes for Trichomoniasis

UMLS symptoms related to Trichomoniasis:


fever, pruritus, pelvic pain

Drugs & Therapeutics for Trichomoniasis

Drugs for Trichomoniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Metronidazole Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 443-48-1 4173
3
Clotrimazole Approved, Vet_approved Phase 4,Phase 3 23593-75-1 2812
4
Clindamycin Approved, Vet_approved Phase 4,Early Phase 1 18323-44-9 29029
5
Tinidazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 19387-91-8 5479
6
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
7 Antiviral Agents Phase 4,Phase 2,Phase 1,Not Applicable
8 Expectorants Phase 4
9 N-monoacetylcystine Phase 4
10 Free Radical Scavengers Phase 4
11 Protective Agents Phase 4,Phase 3
12 Antidotes Phase 4
13 Antibiotics, Antitubercular Phase 4,Phase 3
14 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Respiratory System Agents Phase 4
17 Antioxidants Phase 4
18 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 cysteine Phase 4
20 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Contraceptive Agents Phase 4,Phase 3,Not Applicable
22 Clindamycin palmitate Phase 4,Early Phase 1
23 Clindamycin phosphate Phase 4,Early Phase 1
24
Ethanol Approved Phase 2, Phase 3,Phase 3,Not Applicable 64-17-5 702
25
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Early Phase 1 22916-47-8 4189
26
Secnidazole Approved Phase 3 3366-95-8
27
Fluconazole Approved, Investigational Phase 3,Early Phase 1 86386-73-4 3365
28
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
29
Neomycin Approved, Vet_approved Phase 3 1404-04-2 8378
30
Polymyxin B Approved, Vet_approved Phase 3 1404-26-8
31
leucovorin Approved Phase 3 58-05-9 143 6006
32
Azithromycin Approved Phase 3,Phase 2 83905-01-5 447043 55185
33
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
34
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
35
Iron Approved, Experimental Phase 3 7439-89-6, 15438-31-0 27284 23925
36
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
37
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
38
Histamine Approved, Investigational Phase 3 51-45-6 774
39
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
40
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
41
Acetaminophen Approved Phase 3 103-90-2 1983
42
ofatumumab Approved Phase 3 679818-59-8 6918251
43
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
44
Cetirizine Approved Phase 3 83881-51-0 2678
45
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
47
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
48
Piperaquine Experimental, Investigational Phase 3 4085-31-8 5079497
49
Dihydroartemisinin Experimental, Investigational Phase 3 71939-50-9 6918483
50
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7

Interventional clinical trials:

(show top 50) (show all 95)
# Name Status NCT ID Phase Drugs
1 Role of N-Acetylcysteine in Treatment of Bacterial Vaginosis Unknown status NCT01841411 Phase 4 N-Acetyl cysteine;Metronidazole + N-Acetyl cysteine;metronidazole
2 Trichomonas Vaginalis Recurrence Among HIV+ Women Completed NCT01018095 Phase 4 Metronidazole
3 Stage Matched Intervention to Increase Dual Method Use Completed NCT00436306 Phase 4
4 Comparison of Two Topical Formulations Containing Clindamycin and Clotrimazole in Patients With Vaginal Infections Completed NCT01697826 Phase 4 ClinSupV3 -soft gelatin capsule;ClinSupV3ER- Extended release tablet
5 Evaluation of Efficacy and Safety of Gynomax® XL Ovule Not yet recruiting NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
6 Trichomonas Vaginalis Repeat Infections Among HIV Negative Women Completed NCT01832480 Phase 3 MTZ 500 mg twice daily x 7 days;MTZ 2 g
7 Intravaginal Treatment of Disturbances of Vaginal Flora Among HIV Infected and Uninfected Women in Malawi Completed NCT00140764 Phase 3 Metronidazole gel versus placebo gel
8 Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission Completed NCT00213083 Phase 3 Carraguard (PC-515)
9 Reducing Sexual Risk Behaviors and Improving Health for People at a Sexually Transmitted Infection Clinic Completed NCT00947271 Phase 3
10 Effect of HIV/STD Risk Reduction Program on South African Adolescents Completed NCT00559403 Phase 2, Phase 3
11 Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge Completed NCT02111629 Phase 3 Fluconazole and Secnidazole
12 Effectiveness of a Community-level HIV/STD Prevention Intervention in Promoting Safer Sexual Behaviors in High-risk Populations Completed NCT00710060 Phase 3
13 Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis Completed NCT02515656 Phase 3 POLYGYNAX®;GYNODAKTARIN®;Placebo
14 A Multicenter, Open-Label, Non-Comparative Study of the Safety and Contraceptive Efficacy of the Woman's Condom Completed NCT01223313 Phase 3
15 Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments Completed NCT00313131 Phase 3 tinidazole+fluconazole vs metronidazole+clotrimazole
16 MEMA Kwa Vijana Trial: Impact of an Adolescent Sexual and Reproductive Health Intervention in Mwanza, Tanzania Completed NCT00248469 Phase 3
17 Gestational Sulfadoxine-pyrimethamine and Azithromycin Treatment to Prevent Preterm Birth Completed NCT00131235 Phase 3 Sulfadoxine-pyrimethamine treatment twice during pregnancy;Sulfadoxine-pyrimethamine at 4-week intervals;Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice
18 Supplementing Maternal and Infant Diet With High-energy, Micronutrient Fortified Lipid-based Nutrient Supplements (LNS) Completed NCT01239693 Phase 3
19 A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis Recruiting NCT03935217 Phase 3 Secnidazole;Placebo
20 Improving PRegnancy Outcomes With Intermittent preVEntive Treatment in Africa Not yet recruiting NCT03208179 Phase 3 dihydroartemisinin-piperaquine;sulphadoxine-pyrimethamine;dihydroartemisinin-piperaquine plus azithromycin
21 Preventing Young Infant Infections Using Azithromycin in Labour (PreYIAL) Trial Not yet recruiting NCT03925480 Phase 3 Azithromycin 500 mg Oral Tablet x 4;Matching Placebo
22 Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa Terminated NCT01103063 Phase 3 Azithromycin plus chloroquine;sulfadoxine-pyrimethamine
23 Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris Terminated NCT02613910 Phase 3 Ofatumumab;Acetaminophen/paracetamol;Antihistamine (cetirizine or equivalent);Prednisone/Prednisolone
24 Effectiveness of the Diaphragm for HIV Prevention Withdrawn NCT00121459 Phase 3
25 Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis Completed NCT01361048 Phase 2 oral metronidazole;neo penotran forte;neo penotran forte once a day
26 Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women Completed NCT01230814 Phase 2 Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate);Placebo
27 Study to Improve Partner Services for STD Prevention Completed NCT00207467 Phase 2
28 HIV/STI Risk Reduction for Incarcerated Women With Interpersonal Violence Completed NCT01907126 Phase 2
29 Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing HIV/STI Transmission Completed NCT00213018 Phase 2 Carraguard (PC-515)
30 Safety, Acceptability and Preliminary Effectiveness of PC-515 for Vaginal Use as a Possible Microbicide Completed NCT00213031 Phase 2 Carraguard (PC-515)
31 The Multimedia HIV/STI Prevention for Drug-Involved Female Offenders Completed NCT01784809 Phase 2
32 Behavioral Intervention to Reduce Sexual and Injection Risks Among Female Sex Workers Who Also Inject Drugs in Mexico Completed NCT00840658 Phase 2
33 Safer Sex Program for Young African-American Men Completed NCT01439503 Phase 2
34 A Web-based Intervention Study to Reduce High-risk Sexual Behavior by Persons Living With HIV AIDS (PLWH) Completed NCT01198418 Phase 1, Phase 2
35 NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole) Completed NCT00322465 Phase 2 Tinidazole;Doxycycline;Azithromycin
36 BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women Completed NCT00074425 Phase 2 BufferGel;PRO 2000/5 Gel;Placebo gel
37 Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB Active, not recruiting NCT02748356 Phase 2 Lactobacillus
38 Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB Active, not recruiting NCT02748317 Phase 2 Lactobacillus rhamnosus GG
39 Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South Africa Withdrawn NCT02462772 Phase 2 cabotegravir;Placebo
40 Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions Completed NCT01591889 Phase 1 Tinidazole;Tinidazole
41 Safety and Acceptability of Carraguard™ Among HIV-negative Couples in Thailand Completed NCT00213057 Phase 1 Carraguard (PC-515)
42 S.T.A.R.S.: Sistas Talking About Real Solutions Completed NCT01028157 Phase 1
43 Safety and Pharmacokinetic Trial in Healthy HIV-Negative Women to Assess the Delivery of Dapivirine From a Vaginal Ring Completed NCT02920827 Phase 1
44 A Safety Study to Assess the Delivery of Dapivirine From a Matrix Vaginal Ring Completed NCT01144676 Phase 1 dapivirine;placebo;dapivirine;placebo
45 A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in Belgium Withdrawn NCT01242579 Phase 1 Maraviroc/Dapivirine Gel;Dapivirine Vaginal Gel;Maraviroc Vaginal Gel;Matching Placebo Gel
46 Accuracy and Acceptability of Self-Diagnostic Methods for Vaginitis in Adolescent Females Unknown status NCT00706368 Not Applicable
47 The Impact of Short-term Financial Incentives on Sexual Behavior and HIV Incidence in Lesotho Unknown status NCT01589965 Early Phase 1
48 Rwanda VMB Restoration Study Unknown status NCT02459665 Not Applicable Prophylactic use of metronidazole pills (500 mg)
49 The Contraceptive Choice Project Unknown status NCT01986439
50 Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method Unknown status NCT02558179

Search NIH Clinical Center for Trichomoniasis

Cochrane evidence based reviews: trichomonas infections

Genetic Tests for Trichomoniasis

Anatomical Context for Trichomoniasis

MalaCards organs/tissues related to Trichomoniasis:

42
Testes, Spinal Cord, Cervix, T Cells, Skin, Colon, Tonsil

Publications for Trichomoniasis

Articles related to Trichomoniasis:

(show top 50) (show all 675)
# Title Authors Year
1
Controlled delivery of the antiprotozoal agent (tinidazole) from intravaginal polymer matrices for treatment of the sexually transmitted infection, trichomoniasis. ( 29799300 )
2019
2
Survey of Obstetrician-gynecologists in the United States About Trichomoniasis, 2016. ( 29994936 )
2019
3
Aptima Trichomonas vaginalis assay elucidates significant underdiagnosis of trichomoniasis among women in Brazil according to an observational study. ( 30154157 )
2019
4
Incidence and predictors of reinfection with trichomoniasis based on nucleic acid amplification testing results in HIV-infected patients. ( 30486764 )
2019
5
Treatment recommendations for trichomoniasis in women. ( 30587286 )
2019
6
Trichomonas vaginalis virus (TVV) among women with trichomoniasis and associations with demographics, clinical outcomes, and metronidazole resistance. ( 30768180 )
2019
7
Longitudinal trajectory of vulvovaginal candidiasis, trichomoniasis, and bacterial vaginosis during pregnancy as well as the impact on pregnancy outcomes: a preliminary study. ( 29685081 )
2018
8
A retrospective epidemiological analysis of shared risk factors for bovine trichomoniasis and bovine genital campylobacteriosis in La Pampa province (Argentina). ( 30466651 )
2018
9
The dawn of novel STI prevention methods: modelling potential unintended effects of changes in cervical cancer screening guidelines on trichomoniasis. ( 29545472 )
2018
10
An evaluation study of the Becton-Dickinson ProbeTec Qx (BDQx) Trichomonas vaginalis trichomoniasis molecular diagnostic test in two large, urban STD services. ( 28108699 )
2018
11
Intravaginal boric acid: is it an alternative therapeutic option for vaginal trichomoniasis? ( 29223972 )
2018
12
Is there an association between trichomoniasis and other sexually transmitted infections in adolescent ED patients? ( 29229536 )
2018
13
Humoral and T cell-mediated immune response against trichomoniasis. ( 29266263 )
2018
14
Chlorinated metronidazole as a promising alternative for treating trichomoniasis. ( 29502297 )
2018
15
Incidence of Antenatal Trichomoniasis and Evaluation of Its Role as a Cause of Preterm Birth in Pregnant Women Referring to Minia University Hospital, Egypt. ( 29963086 )
2018
16
The Prevalence of Trichomoniasis in Women Referred to Clinical Centers in South of Tehran, Iran during 2015-2016. ( 29963092 )
2018
17
Metronidazole-Resistant Trichomoniasis: Beneficial Pharmacodynamic Relationship with High-dose Oral Tinidazole and Vaginal Paromomycin Combination Therapy. ( 30106840 )
2018
18
The need for new treatment recommendations for trichomoniasis among women. ( 30297321 )
2018
19
Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial. ( 30297322 )
2018
20
New treatment recommendations for trichomoniasis in women. ( 30507449 )
2018
21
Chemotherapeutic options for the treatment of human trichomoniasis. ( 30612993 )
2018
22
Is It Time to Stop Using Single Dose Oral Metronidazole for the Treatment of Trichomoniasis in Women? ( 30657463 )
2018
23
Prevalence and genotyping of Trichomonas infections in wild birds in central Germany. ( 30092001 )
2018
24
Diagnosis of trichomoniasis in men by urine cytology. ( 27636204 )
2017
25
Challenges and Persistent Questions in the Treatment of Trichomoniasis. ( 27697044 )
2017
26
Single-Dose Compared With Multidose Metronidazole for the Treatment of Trichomoniasis in Women: A Meta-Analysis. ( 27898571 )
2017
27
A Study on the Prevalence of Genital Trichomoniasis among Female Outpatients Attending Sexually Transmitted Infection Clinic in a Tertiary Care Hospital. ( 28042211 )
2017
28
Antitrichomonal activity of Peganum harmala alkaloid extract against trichomoniasis in pigeon (Columba livia domestica). ( 28084792 )
2017
29
A missed diagnosis of trichomoniasis. ( 28085787 )
2017
30
Natural Products as New Treatment Options for Trichomoniasis: A Molecular Docking Investigation. ( 28134827 )
2017
31
Recombinant α-actinin subunit antigens of Trichomonas vaginalis as potential vaccine candidates in protecting against trichomoniasis. ( 28209207 )
2017
32
The prevalence of trichomoniasis and associated factors among women treated at a university hospital in southern Brazil. ( 28346531 )
2017
33
Report of the first clinical case of intestinal trichomoniasis caused by Tritrichomonas foetus in a cat with chronic diarrhoea in Brazil. ( 28412947 )
2017
34
Very low sensitivity of wet mount microscopy compared to PCR against culture in the diagnosis of vaginal trichomoniasis in Uganda: a cross sectional study. ( 28683790 )
2017
35
Diagnosis of Trichomoniasis in Male Patients on Performing Nested Polymerase Chain Reaction. ( 29035239 )
2017
36
Trichomoniasis and associated co-infections of the genital tract among pregnant women presenting at two hospitals in Ghana. ( 29237446 )
2017
37
Prevalence of asymptomatic infections in sexually transmitted diseases attendees diagnosed with bacterial vaginosis, vaginal candidiasis, and trichomoniasis. ( 27890946 )
2016
38
A review of sexually transmitted bovine trichomoniasis and campylobacteriosis affecting cattle reproductive health. ( 26679515 )
2016
39
Can trichomoniasis cause pharyngitis? A case report. ( 28228954 )
2016
40
Comparative aspects of immunity and vaccination in human and bovine trichomoniasis: a review. ( 26424377 )
2016
41
COMPARISON OF PERMANENT STAINING METHODS FOR THE LABORATORY DIAGNOSIS OF TRICHOMONIASIS. ( 26910452 )
2016
42
First report of an outbreak trichomoniasis in turkey in Sistan, Iran. ( 27065599 )
2016
43
Comparative analysis of syndromic and PCR-based diagnostic assay reveals misdiagnosis/ overtreatment for trichomoniasis based on subjective judgment in symptomatic patients. ( 27146362 )
2016
44
Prevalence of Trichomoniasis by PCR in Women Attending Health Screening in Korea. ( 27180577 )
2016
45
Rapid Antigen Testing for Trichomoniasis in an Emergency Department. ( 27207490 )
2016
46
A molecular-beacon-based asymmetric PCR assay for easy visualization of amplicons in the diagnosis of trichomoniasis. ( 27318568 )
2016
47
Trichomoniasis immunity and the involvement of the purinergic signaling. ( 27793265 )
2016
48
Trichomoniasis in older individuals: a preliminary report from Iran. ( 27876991 )
2016
49
Epidemiology of Trichomoniasis in South Korea and Increasing Trend in Incidence, Health Insurance Review and Assessment 2009-2014. ( 27936227 )
2016
50
Prevalence of Trichomoniasis among 18-48 Year-old Women in Northwest of Iran. ( 28127371 )
2016

Variations for Trichomoniasis

Expression for Trichomoniasis

Search GEO for disease gene expression data for Trichomoniasis.

Pathways for Trichomoniasis

Pathways related to Trichomoniasis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.01 CXCL8 IL2 IRF6
2
Show member pathways
10.76 CXCL8 IL2

GO Terms for Trichomoniasis

Cellular components related to Trichomoniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.1 ATAD2 IRF6 LAP3 SLPI TSPAN6 WASF3

Sources for Trichomoniasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....